Vicebio's approach focuses on developing multivalent vaccines that are not only easy to manufacture but also effective against multiple respiratory virus strains, aiming for a competitive edge.
The novel molecular clamp technology allows Vicebio to lock proteins in a perfusion shape, boosting the immune response and simplifying the manufacturing process for vaccines.
The recent $100 million Series B funding will support Vicebio's clinical trial for VXB-241, a vaccine targeting RSV and hMPV, critical for vulnerable populations.
Led by TCGX, the financing round will help expand Vicebio's portfolio with additional vaccines, including combo shots for RSV, hMPV, and PIV3.
Collection
[
|
...
]